Quanta Therapeutics Presents QTX3034 at Major Cancer Conference
Quanta Therapeutics, a pioneering biopharmaceutical firm, is making waves with its innovative treatment options aimed at RAS-driven cancers. This private, clinical-stage company is gearing up to showcase its exciting findings on the oral G12D-preferring multi-KRAS inhibitor, QTX3034, at a significant international conference dedicated to cancer research. Attendees can expect insights into the initial Phase 1 clinical data from their ongoing study.
About QTX3034 Development
QTX3034 is positioned as a novel therapy targeting patients with KRASG12D mutations. These mutations are known contributors to the development and progression of various solid tumors, making this research pivotal for treatment avenues. The upcoming presentation at the conference will detail the safety, tolerability, pharmacokinetics, and preliminary efficacy of QTX3034, elucidating its potential role in transforming patient care.
Conference Details
The presentation is scheduled to take place during the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, occurring from October 22-26. Specifically, Quanta will present on October 24, offering attendees a glimpse into how QTX3034 interacts within clinical settings. The session, labeled 'Spotlight on Proffered Papers 2', will feature Dr. Ignacio Garrido-Laguna from the Huntsman Cancer Institute, who will lead the discussion on these groundbreaking initial findings.
Highlighting Research and Presentations
Additionally, the results will be shared in a poster presentation that day, allowing for further dialogue and inquiry among specialists in the field. This dual presentation approach signifies Quanta's commitment to making its research accessible and fostering collaboration within the oncology community.
Insights into QTX3034's Mechanism of Action
QTX3034 stands out for its ability to preferentially inhibit G12D mutations in KRAS, a notable challenge in current cancer therapies. The drug is not only assessed in isolation but also evaluated in combination with established treatments like cetuximab. This multifaceted approach aims to amplify therapeutic benefits, particularly for patients battling challenging cancers such as pancreatic and colorectal types that exhibit G12D mutations.
Quanta Therapeutics - A Leader in Cancer Treatment Innovation
Founded with the vision of addressing the complexities of RAS-driven oncogenesis, Quanta Therapeutics leverages cutting-edge technology to identify and develop novel small-molecule therapies. Utilizing Second Harmonic Generation technology, the company discovers allosteric modulators that can effectively disrupt the protein-protein interactions fundamental to RAS activity, setting the stage for potentially groundbreaking advancements in cancer treatment.
Building a Strong Portfolio
Quanta currently boasts a robust pipeline that includes not only QTX3034 but also QTX3544, another promising multi-KRAS inhibitor targeting the G12V mutation. By exploring various mutations, Quanta is committed to paving the way for precision medicine in oncology, delivering targeted interventions tailored to the genetic profiles of individual tumors.
Contact Details
For further inquiries, Quanta Therapeutics encourages interested parties to reach out to Heather Meeks at 661-992-6907 or via email. Additionally, media inquiries can be directed to Kelli Perkins via email. Quanta Therapeutics is headquartered in South San Francisco, positioned at the forefront of innovative cancer treatment research and development.
Frequently Asked Questions
What is QTX3034?
QTX3034 is an oral multi-KRAS inhibitor specifically designed to target the G12D mutation in KRAS, which is involved in various solid tumors.
When will the Phase 1 clinical data for QTX3034 be presented?
The data will be unveiled at the 2025 AACR-NCI-EORTC International Conference, on October 24, 2025.
Who will present the findings on QTX3034?
Dr. Ignacio Garrido-Laguna from the Huntsman Cancer Institute will present the initial findings at the conference.
What other trials is Quanta Therapeutics conducting?
In addition to QTX3034, Quanta is also conducting trials for QTX3544, which targets G12V mutations.
How can I get more information about Quanta Therapeutics?
Further details can be obtained by contacting Quanta Therapeutics directly or visiting their official website.
